The Relationship between SNAP25 and Some Common Human Neurological Syndromes


Citar

Texto integral

Resumo

:Over the years, research on the pathogenesis of neurological diseases has progressed slowly worldwide. However, as the incidence rate continues to increase and the disease gradually develops, early diagnosis and treatment have become a top priority. SANP25, a protein present on the presynaptic membrane and involved in neurotransmitter release, is closely related to the loss or abnormal expression of synapses and neurons. SNAP25 deficiency can lead to synaptic disorders and inhibit neurotransmitter release. Therefore, a large amount of literature believes that SNAP25 gene mutation is a risk factor for many neurological diseases. This review used advanced search on PubMed to conduct extensive article searches for relevant literature. The search keywords included SNAP25 and Alzheimer's disease, SNAP25 and Parkinson's disease, and so on. After reading and summarizing the previous papers, the corresponding conclusions were obtained to achieve the purpose of the review. The deficiency or variation of SNAP25 might be related to the onset of schizophrenia, epilepsy, attention deficit/hypoactivity disorder, bipolar disorder effective disorder, and autism. SNAP25 has been found to be used as a neuropathological marker for neurological diseases, which could be the target of diagnosis or treatment of Alzheimer’s disease and Parkinson’s disease. Cerebrospinal Fluid (CSF) or blood has been found to enable more effective drug development.

Sobre autores

Jie Shu

Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University

Email: info@benthamscience.net

Fan Peng

Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University

Email: info@benthamscience.net

Jing Li

Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University

Email: info@benthamscience.net

Yuhang Liu

Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University

Email: info@benthamscience.net

Xiaolan Li

College of Basic Medicine,, The Second People’s Hospital of China Three Gorges University

Autor responsável pela correspondência
Email: info@benthamscience.net

Chengfu Yuan

Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University

Autor responsável pela correspondência
Email: info@benthamscience.net

Bibliografia

  1. Alten B, Zhou Q, Shin OH, et al. Role of aberrant spontaneous neurotransmission in SNAP25-associated encephalopathies. Neuron 2021; 109(1): 59-72.e5. doi: 10.1016/j.neuron.2020.10.012 PMID: 33147442
  2. Houenou J, Boisgontier J, Henrion A, et al. A multilevel functional study of a SNAP25 at-risk variant for bipolar disorder and schizophrenia. J Neurosci 2017; 37(43): 10389-97. doi: 10.1523/JNEUROSCI.1040-17.2017 PMID: 28972123
  3. Uzay B, Kavalali ET. Genetic disorders of neurotransmitter release machinery. Front Synaptic Neurosci 2023; 15: 1148957. doi: 10.3389/fnsyn.2023.1148957 PMID: 37066095
  4. McGrowder DA, Miller F, Vaz K, et al. Cerebrospinal fluid biomarkers of Alzheimer’s disease: Current evidence and future perspectives. Brain Sci 2021; 11(2): 215. doi: 10.3390/brainsci11020215 PMID: 33578866
  5. Kovács-Nagy R, Hu J, Rónai Z, Sasvári-Székely M. SNAP-25: A novel candidate gene in psychiatric genetics. Neuropsychopharmacol Hung 2009; 11(2): 89-94. PMID: 19827316
  6. Zhang H, Zhu S, Zhu Y, Chen J, Zhang G, Chang H. An association study between SNAP-25 gene and attention-deficit hyperactivity disorder. Eur J Paediatr Neurol 2011; 15(1): 48-52. doi: 10.1016/j.ejpn.2010.06.001 PMID: 20599404
  7. Zhang H, Therriault J, Kang MS, et al. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer’s disease. Alzheimers Res Ther 2018; 10(1): 80. doi: 10.1186/s13195-018-0407-6 PMID: 30115118
  8. Antonucci F, Corradini I, Fossati G, Tomasoni R, Menna E, Matteoli M. SNAP-25, a known presynaptic protein with emerging postsynaptic functions. Front Synaptic Neurosci 2016; 8: 7. doi: 10.3389/fnsyn.2016.00007 PMID: 27047369
  9. Høgh P. Alzheimer’s disease. Ugeskr Laeger 2017; 179(12): V09160686. PMID: 28330540
  10. Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol 2018; 25(1): 59-70. doi: 10.1111/ene.13439 PMID: 28872215
  11. Apostolova LG, Hwang KS, Andrawis JP, et al. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging 2010; 31(8): 1284-303. doi: 10.1016/j.neurobiolaging.2010.05.003 PMID: 20538372
  12. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. Lancet 2011; 377(9770): 1019-31. doi: 10.1016/S0140-6736(10)61349-9 PMID: 21371747
  13. Wang Q, Tao S, Xing L, et al. SNAP25 is a potential target for early stage Alzheimer’s disease and Parkinson’s disease. Eur J Med Res 2023; 28(1): 570. doi: 10.1186/s40001-023-01360-8 PMID: 38053192
  14. Sui X, Liu J, Yang X. Cerebrospinal fluid biomarkers of Alzheimer’s disease. Neurosci Bull 2014; 30(2): 233-42. doi: 10.1007/s12264-013-1412-1 PMID: 24733653
  15. Najera K, Fagan BM, Thompson PM. SNAP-25 in major psychiatric disorders: A review. Neuroscience 2019; 420: 79-85. doi: 10.1016/j.neuroscience.2019.02.008 PMID: 30790667
  16. Öhrfelt A, Brinkmalm A, Dumurgier J, et al. A novel ELISA for the measurement of cerebrospinal fluid SNAP-25 in patients with Alzheimer’s disease. Neuroscience 2019; 420: 136-44. doi: 10.1016/j.neuroscience.2018.11.038 PMID: 30528858
  17. Blennow K, Zetterberg H. Biomarkers for Alzheimer’s disease: Current status and prospects for the future. J Intern Med 2018; 284(6): 643-63. doi: 10.1111/joim.12816 PMID: 30051512
  18. Karmakar S, Sharma LG, Roy A, Patel A, Pandey LM. Neuronal SNARE complex: A protein folding system with intricate protein-protein interactions, and its common neuropathological hallmark, SNAP25. Neurochem Int 2019; 122: 196-207. doi: 10.1016/j.neuint.2018.12.001 PMID: 30517887
  19. Pereira JB, Janelidze S, Ossenkoppele R, et al. Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease. Brain 2021; 144(1): 310-24. doi: 10.1093/brain/awaa395 PMID: 33279949
  20. Agostini S, Mancuso R, Liuzzo G, et al. Serum miRNAs expression and SNAP-25 genotype in Alzheimer’s disease. Front Aging Neurosci 2019; 11: 52. doi: 10.3389/fnagi.2019.00052 PMID: 30914946
  21. Ren Z, Yu J, Wu Z, et al. MicroRNA-210-5p contributes to cognitive impairment in early vascular dementia rat model through targeting snap25. Front Mol Neurosci 2018; 11: 388. doi: 10.3389/fnmol.2018.00388 PMID: 30483048
  22. Jia L, Zhu M, Kong C, et al. Blood neuro-exosomal synaptic proteins predict Alzheimer’s disease at the asymptomatic stage. Alzheimers Dement 2021; 17(1): 49-60. doi: 10.1002/alz.12166 PMID: 32776690
  23. Fowler KD, Funt JM, Artyomov MN, Zeskind B, Kolitz SE, Towfic F. Leveraging existing data sets to generate new insights into Alzheimer’s disease biology in specific patient subsets. Sci Rep 2015; 5(1): 14324. doi: 10.1038/srep14324 PMID: 26395074
  24. Brinkmalm A, Brinkmalm G, Honer WG, et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease. Mol Neurodegener 2014; 9(1): 53. doi: 10.1186/1750-1326-9-53 PMID: 25418885
  25. Hayes MT. Parkinson’s disease and parkinsonism. Am J Med 2019; 132(7): 802-7. doi: 10.1016/j.amjmed.2019.03.001 PMID: 30890425
  26. Beitz JM. Parkinson's disease a review. Front Biosci 2014; S6(1): 65-74. doi: 10.2741/S415 PMID: 24389262
  27. Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol 2021; 20(5): 385-97. doi: 10.1016/S1474-4422(21)00030-2 PMID: 33894193
  28. Nakata Y, Yasuda T, Fukaya M, et al. Accumulation of α-synuclein triggered by presynaptic dysfunction. J Neurosci 2012; 32(48): 17186-96. doi: 10.1523/JNEUROSCI.2220-12.2012 PMID: 23197711
  29. Garcia-Reitböck P, Anichtchik O, Bellucci A, et al. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson’s disease. Brain 2010; 133(7): 2032-44. doi: 10.1093/brain/awq132 PMID: 20534649
  30. Caminiti SP, Presotto L, Baroncini D, et al. Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson’s disease. Neuroimage Clin 2017; 14: 734-40. doi: 10.1016/j.nicl.2017.03.011 PMID: 28409113
  31. Agliardi C, Meloni M, Guerini FR, et al. Oligomeric α-Syn and SNARE complex proteins in peripheral extracellular vesicles of neural origin are biomarkers for Parkinson’s disease. Neurobiol Dis 2021; 148: 105185. doi: 10.1016/j.nbd.2020.105185 PMID: 33217562
  32. Gorenberg EL, Chandra SS. The role of co-chaperones in synaptic proteostasis and neurodegenerative disease. Front Neurosci 2017; 11: 248. doi: 10.3389/fnins.2017.00248 PMID: 28579939
  33. Bereczki E, Bogstedt A, Höglund K, et al. Synaptic proteins in CSF relate to Parkinson’s disease stage markers. NPJ Parkinsons Dis 2017; 3(1): 7. doi: 10.1038/s41531-017-0008-2 PMID: 28649607
  34. Huang J, Liu L, Qin L, Huang H, Li X. Weighted gene coexpression network analysis uncovers critical genes and pathways for multiple brain regions in Parkinson’s disease. BioMed Res Int 2021; 2021: 1-46. doi: 10.1155/2021/6616434 PMID: 33791366
  35. Richetto J, Meyer U. Epigenetic modifications in schizophrenia and related disorders: Molecular scars of environmental exposures and source of phenotypic variability. Biol Psychiatry 2021; 89(3): 215-26. doi: 10.1016/j.biopsych.2020.03.008 PMID: 32381277
  36. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet 2016; 388(10039): 86-97. doi: 10.1016/S0140-6736(15)01121-6 PMID: 26777917
  37. Yang H, Zhang M, Shi J, et al. Brain-specific SNAP-25 deletion leads to elevated extracellular glutamate level and schizophrenia like behavior in mice. Neural Plast 2017; 2017: 1-11. doi: 10.1155/2017/4526417 PMID: 29318050
  38. Condliffe SB, Matteoli M. Inactivation kinetics of voltage-gated calcium channels in glutamatergic neurons are influenced by SNAP-25. Channels 2011; 5(4): 304-7. doi: 10.4161/chan.5.4.16228 PMID: 21558797
  39. Ramos-Miguel A, Gicas K, Alamri J, et al. Reduced SNAP25 protein fragmentation contributes to SNARE complex dysregulation in schizophrenia postmortem brain. Neuroscience 2019; 420: 112-28. doi: 10.1016/j.neuroscience.2018.12.015 PMID: 30579835
  40. Barakauskas VE, Moradian A, Barr AM, et al. Quantitative mass spectrometry reveals changes in SNAP-25 isoforms in schizophrenia. Schizophr Res 2016; 177(1-3): 44-51. doi: 10.1016/j.schres.2016.03.002 PMID: 26971072
  41. Ramos-Miguel A, Barakauskas V, Alamri J, et al. The SNAP25 interactome in ventromedial caudate in schizophrenia includes the mitochondrial protein ARF1. Neuroscience 2019; 420: 97-111. doi: 10.1016/j.neuroscience.2018.12.045 PMID: 30610939
  42. Xu C, Sellgren CM, Fatouros-Bergman H, et al. CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects. IBRO Rep 2020; 8: 136-42. doi: 10.1016/j.ibror.2020.04.001 PMID: 32490278
  43. Barakauskas VE, Beasley CL, Barr AM, et al. A novel mechanism and treatment target for presynaptic abnormalities in specific striatal regions in schizophrenia. Neuropsychopharmacology 2010; 35(5): 1226-38. doi: 10.1038/npp.2009.228 PMID: 20072114
  44. Hirschfeld RM, Vornik LA. Bipolar disorder-costs and comorbidity. Am J Manag Care 2005; 11(3) (Suppl.): S85-90. PMID: 16097719
  45. Barnett JH, Smoller JW. The genetics of bipolar disorder. Neuroscience 2009; 164(1): 331-43. doi: 10.1016/j.neuroscience.2009.03.080 PMID: 19358880
  46. Etain B, Dumaine A, Mathieu F, et al. A SNAP25 promoter variant is associated with early-onset bipolar disorder and a high expression level in brain. Mol Psychiatry 2010; 15(7): 748-55. doi: 10.1038/mp.2008.148 PMID: 19125158
  47. Bozzi Y, Casarosa S, Caleo M. Epilepsy as a neurodevelopmental disorder. Front Psychiatry 2012; 3: 19. doi: 10.3389/fpsyt.2012.00019 PMID: 22457654
  48. Watanabe S, Yamamori S, Otsuka S, et al. Epileptogenesis and epileptic maturation in phosphorylation site-specific SNAP-25 mutant mice. Epilepsy Res 2015; 115: 30-44. doi: 10.1016/j.eplepsyres.2015.05.004 PMID: 26220374
  49. Sabers A, Kjær TW. Epilepsy. Ugeskr Laeger 2014; 176(26): V11120634. PMID: 25294573
  50. Hamdan FF, Myers CT, Cossette P, et al. High rate of recurrent de novo mutations in developmental and epileptic encephalopathies. Am J Hum Genet 2017; 101(5): 664-85. doi: 10.1016/j.ajhg.2017.09.008 PMID: 29100083
  51. Klöckner C, Sticht H, Zacher P, et al. De novo variants in SNAP25 cause an early-onset developmental and epileptic encephalopathy. Genet Med 2021; 23(4): 653-60. doi: 10.1038/s41436-020-01020-w PMID: 33299146
  52. Corradini I, Verderio C, Sala M, Wilson MC, Matteoli M. SNAP-25 in neuropsychiatric disorders. Ann N Y Acad Sci 2009; 1152(1): 93-9. doi: 10.1111/j.1749-6632.2008.03995.x PMID: 19161380
  53. Hawi Z, Matthews N, Wagner J, et al. DNA variation in the SNAP25 gene confers risk to ADHD and is associated with reduced expression in prefrontal cortex. PLoS One 2013; 8(4): e60274. doi: 10.1371/journal.pone.0060274 PMID: 23593184
  54. Puentes-Rozo PJ, Acosta-López JE, Cervantes-Henríquez ML, et al. Genetic variation underpinning ADHD risk in a caribbean community. Cells 2019; 8(8): 907. doi: 10.3390/cells8080907 PMID: 31426340
  55. Herken H, Erdal ME, Kenar ANİ, et al. Association of SNAP-25 gene Dde l and Mnl l polymorphisms with adult attention deficit hyperactivity disorder. Psychiatry Investig 2014; 11(4): 476-80. doi: 10.4306/pi.2014.11.4.476 PMID: 25395980
  56. Forero DA, Arboleda GH, Vasquez R, Arboleda H. Candidate genes involved in neural plasticity and the risk for attention-deficit hyperactivity disorder: A meta-analysis of 8 common variants. J Psychiatry Neurosci 2009; 34(5): 361-6. PMID: 19721846
  57. Li J, Yan WJ, Wu Y, Tian XX, Zhang YW. Synaptosomal-associated protein 25 gene polymorphisms affect treatment efficiency of methylphenidate in children with attention-deficit hyperactivity disorder: An fNIRS study. Front Behav Neurosci 2022; 15: 793643. doi: 10.3389/fnbeh.2021.793643 PMID: 35069142
  58. Thapar A, Rutter M. Genetic advances in autism. J Autism Dev Disord 2021; 51(12): 4321-32. doi: 10.1007/s10803-020-04685-z PMID: 32940822
  59. Bolognesi E, Guerini FR, Carta A, et al. The role of SNAP-25 in autism spectrum disorders onset patterns. Int J Mol Sci 2023; 24(18): 14042. doi: 10.3390/ijms241814042 PMID: 37762342
  60. LeBlanc JJ, Fagiolini M. Autism: A "critical period" disorder? Neural Plast 2011; 2011: 1-17. doi: 10.1155/2011/921680 PMID: 21826280
  61. Lenart J, Bratek E, Lazarewicz JW, Zieminska E. Changes in the expression of snap-25 protein in the brain of juvenile rats in two models of autism. J Mol Neurosci 2020; 70(9): 1313-20. doi: 10.1007/s12031-020-01543-6 PMID: 32367505
  62. Braida D, Guerini FR, Ponzoni L, et al. Association between SNAP-25 gene polymorphisms and cognition in autism: Functional consequences and potential therapeutic strategies. Transl Psychiatry 2015; 5(1): e500. doi: 10.1038/tp.2014.136 PMID: 25629685
  63. Choi MG, Kim MJ, Kim DG, Yu R, Jang YN, Oh WJ. Sequestration of synaptic proteins by alpha-synuclein aggregates leading to neurotoxicity is inhibited by small peptide. PLoS One 2018; 13(4): e0195339. doi: 10.1371/journal.pone.0195339 PMID: 29608598
  64. Condliffe SB, Corradini I, Pozzi D, Verderio C, Matteoli M. Endogenous SNAP-25 regulates native voltage-gated calcium channels in glutamatergic neurons. J Biol Chem 2010; 285(32): 24968-76. doi: 10.1074/jbc.M110.145813 PMID: 20522554

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bentham Science Publishers, 2024